Clinical Trials
31 trialsPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Cilengitide in Treating Children With Refractory Primary Brain Tumors
National Cancer Institute (NCI)
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
National Cancer Institute (NCI)
Lobradimil and Carboplatin in Treating Children With Brain Tumors
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Docetaxel in Treating Children With Recurrent Solid Tumors
National Cancer Institute (NCI)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
National Cancer Institute (NCI)
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
National Cancer Institute (NCI)
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)